Fehmi Hindilerden

10PUBLICATIONS
109CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 30, 2026
Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.

|Jan 28, 2026
Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study.

Sema Seçilmiş, Sibel Kabukçu Hacıoğlu, Fehmi Hindilerden

|Aug 06, 2025
The role of CD40L-expressing CXCR5+CD8+ follicular cytotoxic T cells in chronic lymphocytic leukemia.

Fatih Akboga, Fehmi Hindilerden, Ipek Yonal Hindilerden

|Aug 08, 2024
Secondary Solid Cancers in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Multicenter Study

Fehmi Hindilerden, Özge Nuran Akay, Elif Aksoy

|Oct 04, 2023
Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores

Mehmet Baysal, Fehmi Hindilerden, Elif Gülsüm Ümit

|Aug 16, 2023
Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms

İpek Yönal-Hindilerden, Ezgi Şahin, Fehmi Hindilerden

Pageof 2

Frequent Collaborators

6 joint publications

Ipek Yonal-Hindilerden

4 joint publications

Aynur Daglar-Aday

4 joint publications

Meliha Nalçacı

3 joint publications

Emine Gültürk